Plain-English translation of NCT07416474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called RC148, combined with standard chemotherapy, works better than another immunotherapy drug called Tislelizumab, also combined with chemotherapy, for treating advanced squamous lung cancer that has not been treated before. Both groups will receive chemotherapy along with one of these two immunotherapy medications to see which combination helps patients live longer and controls their cancer better.
Advanced squamous lung cancer is a serious diagnosis, and while chemotherapy helps some patients, doctors are looking for better treatment options. This trial exists to find out whether pairing chemotherapy with newer immunotherapy drugs can improve outcomes for patients with this type of cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either RC148 or Tislelizumab, both paired with platinum-based chemotherapy. You will continue this treatment throughout the study period, with regular visits to the clinic for physical exams, blood tests, and imaging scans to monitor how well the treatment is working and manage any side effects. The study involves about 574 participants across multiple hospitals, and your participation will include regular follow-up appointments to track your response to treatment.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China